Targeting FGL2 in Glioma Immunosuppression and Malignant Progression

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Oct 31

PMID 36313679

Authors

Xiaoyu Ma

Hongtao Zhu

Lidong Cheng

Xin Chen

Kai Shu

Suojun Zhang

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is the most malignant type of glioma with the worst prognosis. Traditional therapies (surgery combined with radiotherapy and chemotherapy) have limited therapeutic effects. As a novel therapy emerging in recent years, immunotherapy is increasingly used in glioblastoma (GBM), so we expect to discover more effective immune targets. FGL2, a member of the thrombospondin family, plays an essential role in regulating the activity of immune cells and tumor cells in GBM. Elucidating the role of FGL2 in GBM can help improve immunotherapy efficacy and design treatment protocols. This review discusses the immunosuppressive role of FGL2 in the GBM tumor microenvironment and its ability to promote malignant tumor progression while considering FGL2-targeted therapeutic strategies. Also, we summarize the molecular mechanisms of FGL2 expression on various immune cell types and discuss the possibility of FGL2 and its related mechanisms as new GBM immunotherapy.

Citing Articles

Proteomic analysis of plasma and duodenal tissue in celiac disease patients reveals potential noninvasive diagnostic biomarkers.

Li N, Maimaitireyimu A, Shi T, Feng Y, Liu W, Xue S Sci Rep. 2024; 14(1):29872.

PMID: 39622892 PMC: 11612483. DOI: 10.1038/s41598-024-80391-5.

Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co-expression network analysis.

Han H, Liu J, Zhu S, Zhao T J Cell Mol Med. 2024; 28(14):e18552.

PMID: 39054581 PMC: 11272607. DOI: 10.1111/jcmm.18552.

Unravelling infiltrating T-cell heterogeneity in kidney renal clear cell carcinoma: Integrative single-cell and spatial transcriptomic profiling.

Chen H, Zuo H, Huang J, Liu J, Jiang L, Jiang C J Cell Mol Med. 2024; 28(12):e18403.

PMID: 39031800 PMC: 11190954. DOI: 10.1111/jcmm.18403.

FGL1 and FGL2: emerging regulators of liver health and disease.

Chen J, Wu L, Li Y Biomark Res. 2024; 12(1):53.

PMID: 38816776 PMC: 11141035. DOI: 10.1186/s40364-024-00601-0.

Biomaterial strategies for regulating the neuroinflammatory response.

Galindo A, Frey Rubio D, Hettiaratchi M Mater Adv. 2024; 5(10):4025-4054.

PMID: 38774837 PMC: 11103561. DOI: 10.1039/d3ma00736g.

References

Tekguc M, Wing J, Osaki M, Long J, Sakaguchi S . Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci U S A. 2021; 118(30). PMC: 8325248. DOI: 10.1073/pnas.2023739118. View

Maire C, Mohme M, Bockmayr M, Fita K, Riecken K, Bornigen D . Glioma escape signature and clonal development under immune pressure. J Clin Invest. 2020; 130(10):5257-5271. PMC: 7524465. DOI: 10.1172/JCI138760. View

Liu Y, Xu S, Xiao F, Xiong Y, Wang X, Gao S . The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway. Biochem Biophys Res Commun. 2010; 396(2):555-61. DOI: 10.1016/j.bbrc.2010.04.145. View

Rosenberg S, Restifo N . Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348(6230):62-8. PMC: 6295668. DOI: 10.1126/science.aaa4967. View

Zhao Z, Yang C, Wang L, Li L, Zhao T, Hu L . The regulatory T cell effector soluble fibrinogen-like protein 2 induces tubular epithelial cell apoptosis in renal transplantation. Exp Biol Med (Maywood). 2014; 239(2):193-201. DOI: 10.1177/1535370213514921. View

Gardner A, Ruffell B . Dendritic Cells and Cancer Immunity. Trends Immunol. 2016; 37(12):855-865. PMC: 5135568. DOI: 10.1016/j.it.2016.09.006. View

Liu H, Yang P, Zhu T, Manuel J, Zhang J, He W . Characterization of fibrinogen-like protein 2 (FGL2): monomeric FGL2 has enhanced immunosuppressive activity in comparison to oligomeric FGL2. Int J Biochem Cell Biol. 2012; 45(2):408-18. DOI: 10.1016/j.biocel.2012.10.014. View

Wu K, Lin K, Li X, Yuan X, Xu P, Ni P . Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020; 11:1731. PMC: 7417513. DOI: 10.3389/fimmu.2020.01731. View

Tanaka A, Sakaguchi S . Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019; 49(8):1140-1146. DOI: 10.1002/eji.201847659. View

10.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

11.

Song Z, Wang Y, Du Y, Zhang Z, Yuan Y . Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples. Int Immunopharmacol. 2020; 88:106894. DOI: 10.1016/j.intimp.2020.106894. View

12.

Rubtsov Y, Rasmussen J, Chi E, Fontenot J, Castelli L, Ye X . Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008; 28(4):546-58. DOI: 10.1016/j.immuni.2008.02.017. View

13.

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

14.

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z . Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019; 26(1):78. PMC: 6800990. DOI: 10.1186/s12929-019-0568-z. View

15.

Ghouzlani A, Kandoussi S, Tall M, Reddy K, Rafii S, Badou A . Immune Checkpoint Inhibitors in Human Glioma Microenvironment. Front Immunol. 2021; 12:679425. PMC: 8301219. DOI: 10.3389/fimmu.2021.679425. View

16.

Josefowicz S, Lu L, Rudensky A . Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531-64. PMC: 6066374. DOI: 10.1146/annurev.immunol.25.022106.141623. View

17.

Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

18.

Foerster K, Helmy A, Zhu Y, Khattar R, Adeyi O, Wong K . The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. J Hepatol. 2010; 53(4):608-15. DOI: 10.1016/j.jhep.2010.04.020. View

19.

Han J, Khatwani N, Searles T, Turk M, Angeles C . Memory CD8 T cell responses to cancer. Semin Immunol. 2020; 49:101435. PMC: 7738415. DOI: 10.1016/j.smim.2020.101435. View

20.

Shalev I, Wong K, Foerster K, Zhu Y, Chan C, Maknojia A . The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology. 2008; 49(2):387-97. DOI: 10.1002/hep.22684. View